Evidence map›Paper›PMID 37554550›Full record

ArticleCancer research communications2023

Exploring the Onset and Progression of Prostate Cancer through a Multicellular Agent-based Model.

Margot Passier, Maisa N G van Genderen, Anniek Zaalberg, Jeroen Kneppers, Elise M Bekers, Andries M Bergman, Wilbert Zwart, Federica Eduati

Abstract read
In one paragraph

Article in Cancer research communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Margot PassierDepartment of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands.ORCID 0000-0002-6727-0887
Maisa N G van GenderenDepartment of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands.ORCID 0000-0002-7394-9888
Anniek ZaalbergDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands.ORCID 0000-0001-9573-6448
Jeroen KneppersDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands.ORCID 0000-0002-6548-2480
Elise M BekersDivision of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0001-5159-1697
Andries M BergmanDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands.ORCID 0000-0001-5223-2549
Wilbert ZwartDepartment of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands.ORCID 0000-0002-9823-7289
Federica EduatiDepartment of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands.ORCID 0000-0002-7822-3867

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over 10% of men will be diagnosed with prostate cancer during their lifetime. Arising from luminal cells of the prostatic acinus, prostate cancer is influenced by multiple cells in its microenvironment. To expand our knowledge and explore means to prevent and treat the disease, it is important to understand what drives the onset and early stages of prostate cancer. In this study, we developed an agent-based model of a prostatic acinus including its microenvironment, to allow for Significance: We developed a computational model to study which factors of the tumor microenvironment drive prostate cancer development, with potential to aid the development of new prevention strategies.

Indexed as

Cancer-Associated FibroblastsProstatic NeoplasmsHumansMaleProstateTumor Microenvironment

Identifiers

PMID37554550
PMCPMC10405859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.